

**Minutes
Cincinnati Children's Hospital
Institutional Biosafety Committee**

Meeting Information

Location: Virtual
Date and Time: November 11, 2025 7:30 AM
End Time: 8:45 AM
Chair: Stephen Waggoner

Attendance

Name	Status
Brenna Carey	Member Scientist
Bryan Donnelly	Member Scientist
Marcia Espinola	Member Scientist - Unaffiliated
Buddy Goose	Community Member
James Gulick	Member Scientist
Scott Keely	Community Member
Ian Lewkowich	Member Scientist – Vice Chair
Tamara Rausch	Member Scientist - BSO
Karnail Singh	Member Scientist
Sherry Thornton	Member Scientist
Stephen Waggoner	Member Scientist - Chair
Rathi Kavanaugh	Member – non-voting
Bruce Trapnell	Member – non-voting
Tabitha Dowdy	Biosafety Office
Courtney Roher	Biosafety Office
<i>Quorum</i>	7
<i>Voting</i>	11

Minutes from Previous Meeting

[10.14.25 Minutes.docx\(0.01\)](#)

The meeting minutes from the October 2025 meeting were reviewed by the committee and approved (11 yes; 0 no; 0 abstain).

Expedited Protocols

Study ID	PI	Reviewer
None		

New HRS Protocols

PI:	Hermine Brunner		
Study ID:	<u>IBC2025-0070</u>		
Title:	Descartes-08 for children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis		
Biosafety Items:	HGT		
Primary Reviewer:	Ian Lewkowich		
Secondary Reviewer:	Sherry Thornton		
Ad Hoc Reviewer:	Bruce Trapnell		
Agents:	Human derived materials		
BSL:	BSL-2		
Applicable NIH Guidelines:	Section III-C: <i>Experiments Involving Human Gene Transfer that Require Institutional Biosafety Committee Approval Prior to Initiation</i> Section III-C-1: <i>Experiments Involving the Deliberate Transfer of Recombinant or Synthetic Nucleic Acid Molecules, or DNA or RNA Derived from Recombinant or Synthetic Nucleic Acid Molecules, into One or More Human Research Participants</i>		
Motion:	Modifications Required		
Vote:	Yes: 11	No: 0	Abstain: 0
	Recuse:0		Absent: 0

HRS Protocol Renewals

PI:	John Racadio		
Study ID:	IBC2025-0054		
Title:	Large Animal BSL1/BSL2 Core		
Biosafety Items:	ZC		
Primary Reviewer:	James Gulick		
Secondary Reviewer:	Buddy Goose		
Agents:	Nonhuman derived materials		
BSL:	BSL-2		
Applicable NIH Guidelines:	Section III-F: <i>Exempt experiments</i>		
Motion:	Modifications Required		
Vote:	Yes: 11	No: 0	Abstain: 0
	Recuse:0		Absent: 0

PI:	Tamara Tilburgs		
Study ID:	IBC2025-0072		
Title:	Studies of Placental Inflammation and Infection		
Biosafety Items:	DVPM		
Primary Reviewer:	Marcia Espinola		
Secondary Reviewer:	Brenna Carey		
Agents:	<p>Escherichia coli (strains bearing K1 antigen) Listeria monocytogenes Streptococcus agalactiae Human Derived Blood and Blood Types Amniotic Fluid 293T BEWO HELA HFF-1 HTR-8 JAR JEG-3 K-562 L721.221 NK-92 Primary Human Decidual Stromal Cell Lines Primary Human Trophoblast Cell Lines THP-1 U937 VERO-E6 Human Peripheral Blood Mononuclear Cells Human Primary Umbilical Vein Endothelial Cells Human placenta Cytomegalovirus (Herpesvirus) Zika Virus</p>		
BSL:	BSL-2		
Applicable NIH Guidelines:	Section III-F <i>Exempt Experiments</i>		
Motion:	Modifications Required		
Vote:	Yes: 11	No: 0	Abstain: 0
	Recuse: 0		Absent: 0

PI:	Ziyuan Guo		
Study ID:	IBC2025-0064		
Title:	Human iPSCs derived neurons and brain organoids as model to study neurodevelopmental and neurodegenerative disorders		
Biosafety Items:	DAVM		
Primary Reviewer:	Brenna Carey		

Secondary Reviewer:	Karnail Singh		
Agents:	293T Human iPSC Lines Adeno-Associated Virus Lentivirus		
BSL:	BSL-2		
Applicable NIH Guidelines:	<p>Section III-D-3: <i>Experiments Involving the Use of Infectious DNA or RNA Viruses or Defective DNA or RNA Viruses in the Presence of a Helper System in Tissue Culture Systems</i></p> <p>Section III-D-4-c-(2): <i>The purchase or transfer of BL1 transgenic rodents is exempt from the NIH Guidelines under Section III-F, Exempt Experiments</i></p> <p>Section III-E: <i>Experiments that Require Institutional Biosafety Committee Notice Simultaneous with Initiation</i></p> <p>Section III-E-1: <i>Experiments Involving the Formation of Recombinant or Synthetic Nucleic Acid Molecules Containing No More than Two-Thirds of the Genome of any Eukaryotic Virus</i></p> <p>Section III-E-3-a: <i>Experiments involving the breeding of certain BL1 transgenic rodents are exempt under Section III-F, Exempt Experiments</i></p> <p>Section III-F: Exempt Experiments</p>		
Motion:	Modifications Required		
Vote:	Yes: 11	No: 0	Abstain: 0
	Recuse: 0		Absent: 0

PI:	Paul Spearman
Study ID:	IBC2025-0065
Title:	Basic Research in HIV Biology and Virus-Host Interactions
Biosafety Items:	DVPZM
Primary Reviewer:	Stephen Waggoner
Secondary Reviewer:	Scott Keely
Agents:	Human Derived Blood and Blood Types 293 293T H9 HELA Human iPSC Lines JURKAT MOLT-4 Human Peripheral Blood Mononuclear Cells Human immunodeficiency virus (HIV) types 2 (Retroviruses)

	Lentivirus		
BSL:	BSL2+		
Applicable NIH Guidelines:	<p>Section III-D-3: <i>Experiments Involving the Use of Infectious DNA or RNA Viruses or Defective DNA or RNA Viruses in the Presence of a Helper System in Tissue Culture Systems</i></p> <p>Section III-D-3-a: <i>Experiments involving the use of infectious or defective Risk Group 2 viruses in the presence of a helper system may be conducted at BL2</i></p> <p>Section III-D-3-b: <i>Experiments involving the use of infectious or defective Risk Group 3 viruses in the presence of a helper system may be conducted at BL3</i></p>		
Motion:	Modifications Required		
Vote:	Yes: 11	No: 0	Abstain: 0
	Recuse:0	Absent: 0	

ePAS Protocol Amendments

PI:	Charles Vorhees		
Study ID:	Amendment 2 for IBC2023-0057		
Title:	Animal Behavior Facility		
Biosafety Items:	DAC		
Modification	Addition of AAV		
Primary Reviewer:	Tamara Rausch		
Agents:	AAV		
BSL:	BSL1		
Applicable NIH Guidelines:	Experiments involving the generation or breeding of genetically modified rodents (BSL1 only).		
Motion:	Modifications Required		
Vote:	Yes: 11	No: 0	Abstain: 0
	Recuse:0	Absent: 0	

Discussion items

Skelton/Vorhees/Sunderman Protocol Transfer: Amendment for IBC2024-0083 – Tabitha Dowdy presented the protocol transfer for administrative approval.

December Meeting – In Person